A new US study involving over 2.5 million children finds no link between the timing of the MMR vaccine within the recommended age window and autism risk, offering reassurance for parents and reinforcing existing evidence against a vaccine-autism connection.
A large new US study is offering fresh reassurance for parents who have ever wondered whether the timing of the measles, mumps and rubella jab could play a part in autism risk. According to research published in the Pediatric Infectious Disease Journal, following more than 2.5 million children found no evidence that getting a first MMR dose earlier within the recommended age window changed the likelihood of a later autism diagnosis.
What makes the study useful is the question it actually asked. Rather than comparing vaccinated children with unvaccinated children, it looked at whether receiving MMR nearer the start of the routine window, rather than later, altered risk. In the main analysis, children who had their first dose between 11.5 and 24 months showed an adjusted hazard ratio of 0.97, with a 99% confidence interval of 0.91 to 1.03, which is essentially a null result.
The researchers used a large electronic health record database with linked birth-parent records and followed children from January 2015 through December 2024, with observation continuing until age eight or the last recorded visit. To reduce the risk of misleading results, they used age-based landmark analyses and also tested an unrelated negative control exposure, which likewise came back near null. That matters because vaccine-timing studies can be distorted by differences in healthcare attendance, family behaviour and the fact that early developmental concerns sometimes change when children are seen by clinicians.
For parents, the practical takeaway is straightforward: this study sits neatly alongside a long line of previous work showing no link between MMR and autism. The US Centers for Disease Control and Prevention says extensive studies have found no association, and notes that the vaccine is highly effective at preventing measles, mumps and rubella. Earlier research, including a large Danish cohort, reached the same conclusion, while a CDC review of the long-running controversy points to the original 1998 claim as the start of a debate that later evidence did not support.
That wider context matters because the public-health stakes are not abstract. CDC figures show measles remains a serious disease, with the agency reporting 2,371 confirmed cases in 2026 and a large share among unvaccinated people. For households, the MMR schedule still matters in the ordinary, practical way it always has: the first dose is recommended at 12 to 15 months, the second at four to six years, and children who are behind can usually be caught up. Families with questions, or with children who have complex medical needs, should speak to their paediatrician, especially because MMR is a live vaccine and timing can need individual advice.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
